


## Annex C: Overview of the revised governance pathways



*(1): In case the vaccine development timelines are faster than anticipated and the vaccine is expected to be available before the next Vaccine Investment Strategy (VIS), the teams will evaluate the possibility of an ad-hoc VIS assessment considering information about health benefits, price attractiveness, cost implications, etc.*

*(2): Exceptionally, Gavi Secretariat could reach out to the Market-Sensitive Decisions Committee (MSDC) for guidance on sensitive information prior to submitting the investment case to the Board PPC/Board.*

*In some cases, the Alliance might define specific market conditions that need to be met before starting to procure the next generation vaccine, to ensure market health attributes are met (e.g. vaccine availability and price to Gavi countries, number of prequalified vaccines). These conditions will be shared with relevant manufacturers when available.*